DGAP-News: MorphoSys AG informs about the results of the General Meeting 2022 | News

DGAP-News: MorphoSys AG / Keywords: General Meeting

MorphoSys AG reports on the results of the 2022 Annual General Meeting

05/18/2022 / 22:02
The issuer / publisher is responsible for the content of the application.

Press Release

Planegg / Munich, 18 May 2022

MorphoSys AG reports on the results of the 2022 Annual General Meeting

All the proposed resolutions were adopted

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that the company’s shareholders approved all agenda items that were put to the vote at the annual virtual general meeting on May 18, 2022. This includes the following agenda items:

– Resolution on acknowledging the fulfillment of duties by members of the Management Board and Supervisory Board for the financial year 2021

– Resolution on the selection of PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft as the auditor for the financial year 2022

– Resolution on the selection of dr. Andrew Cheng as a board member

– Resolution on the reduction of the Conditional Capital 2016-III, the Conditional Capital 2020-I and the Target Capital 2019-I; Amendments to the Articles of Association “

– Resolution on the creation of a new Target Capital 2022-I with the exclusion of the pre-emptive right to service the restricted shares issued under the Company’s Restricted Units Program for the management and employees of the Company’s US subsidiaries; Amendments to the Articles of Association “

– Resolution on the approval of the remuneration system for members of the Management Board

– Resolution on the approval of the Compensation Protocol 2021

40.52% of the current share capital was represented at the MorphoSys AG Virtual General Meeting in 2022. The company took advantage of the possibility of holding the Annual General Meeting in 2022 granted by German law in connection with the coronavirus pandemic without the physical presence of shareholders or their proxies. Through a password-protected website, registered shareholders could, inter alia, follow the course of the General Meeting via video and audio transmission, exercise the right to vote and ask questions.

The term of office of Mrs. Wendy Johnson as Supervisory Board member ended with the conclusion of this Annual General Meeting on May 18, 2022. Mrs. Johnson has stated that she will not seek re-election. She was elected to the Supervisory Board in May 2015.

On behalf of my colleagues from the Supervisory Board, I would like to thank Wendy for her dedicated work and valuable support over the years, and I wish you much success for the future, said Dr. Marc Cluzel, Chairman of the Supervisory Board of MorphoSys AG. Welcome dr. Andrew Cheng on the Supervisory Board and we look forward to working with him. Thanks to her vast experience, she will be a valuable support for MorphoSys in the future.

I would like to thank our shareholders for their constant support and trust, also on behalf of the entire Management Board and Executive Committees – said Dr. Jean-Paul Kress, CEO of MorphoSys AG.

More information about the General Meeting, including voting results on all items on the agenda, can be found at www.morphosys.de/hv.

About MorphoSys:
At MorphoSys, we have a clear mission: We want people with Cancer to live better and longer. As a global biopharmaceutical company, we use cutting-edge science and technology to discover, develop, and deliver innovative anti-cancer drugs to patients. MorphoSys is headquartered in Planegg, Germany and another location in Boston, Massachusetts, USA. For more information, visit www.morphosys.de/hv. Follow us on LinkedIn and Twitter.

MorphoSys Forward-Looking Statements
This press release contains certain forward-looking statements regarding the MorphoSys group of companies. They involve known and unknown risks and uncertainties that could cause the actual performance, financial condition, liquidity, performance or achievements of MorphoSys or the performance of the industry to differ materially from historical or future results, financial position, liquidity, performance or achievements expressed or implied by such forward-looking statements. Even if the results, performance, financial health and liquidity of MorphoSys and the development of the industry in which MorphoSys operates are in line with forward-looking statements, they do not indicate performance or development in future periods. Factors that may lead to variations include the fact that MorphoSys expectations may be inaccurate, the inherent uncertainties in competition development, clinical research and product development, and regulatory approval requirements, reliance on third parties, an assessment of the commercial potential of MorphoSys development programs, and other risks identified in the risk factors in the MorphoSys annual report on Form 20-F and other documents of the US Securities and Exchange Commission. Given these uncertainties, the reader is cautioned not to rely unduly on such forward-looking statements. These forward-looking statements speak only as of the date of this document. MorphoSys expressly disclaims any obligation to update the forward-looking statements contained herein to reflect changed expectations or changed events, conditions or circumstances on which such statements are based, or which affect the likelihood that actual results will differ from those contained. in forward-looking statements, unless required to do so by law or regulation.

For more information please contact:

18.05.2022 Publication of Corporate / Financial News broadcast by DGAP – EQS Group AG website.
The issuer / publisher is responsible for the content of the application.

DGAP’s distribution services include statutory reporting, corporate / financial news, and press releases.
Media archive at http://www.dgap.de

Leave a Comment